Edwards Lifesciences Corporation (EW) : Traders are bullish on Edwards Lifesciences Corporation (EW) as it has outperformed the S&P 500 by a margin of 3.63% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.31%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.93% in the last 1 week, and is up 10.63% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
Edwards Lifesciences Corporation (NYSE:EW): The stock opened at $106.20 on Friday but the bulls could not build on the opening and the stock topped out at $106.50 for the day. The stock traded down to $105.28 during the day, due to lack of any buying support eventually closed down at $106.25 with a loss of -0.01% for the day. The stock had closed at $106.26 on the previous day. The total traded volume was 856,350 shares.
The stock has recorded a 20-day Moving Average of 3.88% and the 50-Day Moving Average is 4.85%. Edwards Lifesciences Corp. has dropped 1.92% during the last 3-month period . Year-to-Date the stock performance stands at 34.53%.
Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company is engaged in the development and commercialization of heart valve therapies. It is a manufacturer of heart valve systems and repair products used to replace or repair a patients diseased or defective heart valve. The Company develops hemodynamic monitoring systems used to measure a patients cardiovascular function in the hospital setting. Patients in the hospital setting, including high-risk patients in the operating room or intensive care unit, are candidates for having their cardiac function or fluid levels monitored by the its Critical Care products. The Companys products and technologies it offers to treat advanced cardiovascular disease are categorized into three main areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care.